www.kartosthera.comHealthcareFounded: 2017
Kartos Therapeutics is a clinical stage biopharmaceutical company with a potential best-in-class MDM2 inhibitor (KRT-232) in clinical development, across a variety of TP53 wild-type hematological malignancies and solid tumors.
View Enterprise Value for Kartos Therapeutics.